CA2440683A1 - Automated methods of detecting receptor activity - Google Patents
Automated methods of detecting receptor activity Download PDFInfo
- Publication number
- CA2440683A1 CA2440683A1 CA002440683A CA2440683A CA2440683A1 CA 2440683 A1 CA2440683 A1 CA 2440683A1 CA 002440683 A CA002440683 A CA 002440683A CA 2440683 A CA2440683 A CA 2440683A CA 2440683 A1 CA2440683 A1 CA 2440683A1
- Authority
- CA
- Canada
- Prior art keywords
- intensity
- cell
- energy emitted
- detectable molecules
- gpcr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 69
- 230000000694 effects Effects 0.000 title claims abstract description 23
- 102000005962 receptors Human genes 0.000 title description 28
- 108020003175 receptors Proteins 0.000 title description 28
- 210000004027 cell Anatomy 0.000 claims abstract description 137
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 claims abstract description 130
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 claims abstract description 130
- 102000003916 Arrestin Human genes 0.000 claims abstract description 66
- 108090000328 Arrestin Proteins 0.000 claims abstract description 66
- 239000000556 agonist Substances 0.000 claims abstract description 39
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 39
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 39
- 210000000805 cytoplasm Anatomy 0.000 claims abstract description 25
- 210000003956 transport vesicle Anatomy 0.000 claims abstract description 25
- 230000004807 localization Effects 0.000 claims abstract description 14
- 210000001163 endosome Anatomy 0.000 claims abstract description 12
- 230000001268 conjugating effect Effects 0.000 claims abstract description 8
- 150000001875 compounds Chemical class 0.000 claims description 32
- 238000012360 testing method Methods 0.000 claims description 30
- 230000037361 pathway Effects 0.000 claims description 18
- 239000005557 antagonist Substances 0.000 claims description 7
- 230000008859 change Effects 0.000 claims description 6
- 238000000338 in vitro Methods 0.000 abstract description 5
- 238000001727 in vivo Methods 0.000 abstract description 4
- 241000282414 Homo sapiens Species 0.000 description 32
- 239000005090 green fluorescent protein Substances 0.000 description 23
- 230000026731 phosphorylation Effects 0.000 description 21
- 238000006366 phosphorylation reaction Methods 0.000 description 21
- 238000001514 detection method Methods 0.000 description 16
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 9
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 239000003446 ligand Substances 0.000 description 8
- 230000004913 activation Effects 0.000 description 7
- 230000003834 intracellular effect Effects 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- 210000000170 cell membrane Anatomy 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 230000000638 stimulation Effects 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- 230000011664 signaling Effects 0.000 description 5
- 102000006575 G-Protein-Coupled Receptor Kinases Human genes 0.000 description 4
- 108010008959 G-Protein-Coupled Receptor Kinases Proteins 0.000 description 4
- 102100037108 Vasopressin V2 receptor Human genes 0.000 description 4
- 101710173688 Vasopressin V2 receptor Proteins 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000029918 bioluminescence Effects 0.000 description 4
- 238000005415 bioluminescence Methods 0.000 description 4
- 238000000225 bioluminescence resonance energy transfer Methods 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 108010040718 Neurokinin-1 Receptors Proteins 0.000 description 3
- 102100037346 Substance-P receptor Human genes 0.000 description 3
- 238000004590 computer program Methods 0.000 description 3
- 230000009849 deactivation Effects 0.000 description 3
- 108091006047 fluorescent proteins Proteins 0.000 description 3
- 102000034287 fluorescent proteins Human genes 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 239000012085 test solution Substances 0.000 description 3
- 230000000007 visual effect Effects 0.000 description 3
- 102000008081 Arrestins Human genes 0.000 description 2
- 108010074613 Arrestins Proteins 0.000 description 2
- 108090000835 CX3C Chemokine Receptor 1 Proteins 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 108010070503 PAR-2 Receptor Proteins 0.000 description 2
- 102100037132 Proteinase-activated receptor 2 Human genes 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000004624 confocal microscopy Methods 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 108010082025 cyan fluorescent protein Proteins 0.000 description 2
- 238000000586 desensitisation Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000007876 drug discovery Methods 0.000 description 2
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 230000000984 immunochemical effect Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 108091008880 orphan GPCRs Proteins 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108010054624 red fluorescent protein Proteins 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000005945 translocation Effects 0.000 description 2
- 108091005957 yellow fluorescent proteins Proteins 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- 102100022738 5-hydroxytryptamine receptor 1A Human genes 0.000 description 1
- 102100027499 5-hydroxytryptamine receptor 1B Human genes 0.000 description 1
- 102100036312 5-hydroxytryptamine receptor 1E Human genes 0.000 description 1
- 101150007969 ADORA1 gene Proteins 0.000 description 1
- 108060003345 Adrenergic Receptor Proteins 0.000 description 1
- 102000017910 Adrenergic receptor Human genes 0.000 description 1
- 102100024402 Alpha-1B adrenergic receptor Human genes 0.000 description 1
- 102100025983 Alpha-2C adrenergic receptor Human genes 0.000 description 1
- 102000008873 Angiotensin II receptor Human genes 0.000 description 1
- 108050000824 Angiotensin II receptor Proteins 0.000 description 1
- 102400000059 Arg-vasopressin Human genes 0.000 description 1
- 101800001144 Arg-vasopressin Proteins 0.000 description 1
- 108090000363 Bacterial Luciferases Proteins 0.000 description 1
- 102100040794 Beta-1 adrenergic receptor Human genes 0.000 description 1
- 102100039705 Beta-2 adrenergic receptor Human genes 0.000 description 1
- 102100029649 Beta-arrestin-1 Human genes 0.000 description 1
- 102100029648 Beta-arrestin-2 Human genes 0.000 description 1
- 102100028989 C-X-C chemokine receptor type 2 Human genes 0.000 description 1
- 102000004298 CX3C Chemokine Receptor 1 Human genes 0.000 description 1
- 102100039196 CX3C chemokine receptor 1 Human genes 0.000 description 1
- 102000018208 Cannabinoid Receptor Human genes 0.000 description 1
- 108050007331 Cannabinoid receptor Proteins 0.000 description 1
- 108010089448 Cholecystokinin B Receptor Proteins 0.000 description 1
- 102000005853 Clathrin Human genes 0.000 description 1
- 108010019874 Clathrin Proteins 0.000 description 1
- 102100020802 D(1A) dopamine receptor Human genes 0.000 description 1
- 102100029813 D(1B) dopamine receptor Human genes 0.000 description 1
- 102100020756 D(2) dopamine receptor Human genes 0.000 description 1
- 101710172165 D(2) dopamine receptor Proteins 0.000 description 1
- 102100029815 D(4) dopamine receptor Human genes 0.000 description 1
- 101150097070 Drd3 gene Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108090000331 Firefly luciferases Proteins 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 229940125499 GPCR antagonist Drugs 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 102000001972 Galanin receptor 3 Human genes 0.000 description 1
- 108050009372 Galanin receptor 3 Proteins 0.000 description 1
- 102000052874 Gastrin receptors Human genes 0.000 description 1
- 102100022662 Guanylyl cyclase C Human genes 0.000 description 1
- 101710198293 Guanylyl cyclase C Proteins 0.000 description 1
- 101000822895 Homo sapiens 5-hydroxytryptamine receptor 1A Proteins 0.000 description 1
- 101000724725 Homo sapiens 5-hydroxytryptamine receptor 1B Proteins 0.000 description 1
- 101000783609 Homo sapiens 5-hydroxytryptamine receptor 1E Proteins 0.000 description 1
- 101000689698 Homo sapiens Alpha-1B adrenergic receptor Proteins 0.000 description 1
- 101000931925 Homo sapiens D(1A) dopamine receptor Proteins 0.000 description 1
- 101000865210 Homo sapiens D(1B) dopamine receptor Proteins 0.000 description 1
- 101000865206 Homo sapiens D(4) dopamine receptor Proteins 0.000 description 1
- 101000598887 Homo sapiens Olfactory receptor 6A2 Proteins 0.000 description 1
- 101000693265 Homo sapiens Sphingosine 1-phosphate receptor 1 Proteins 0.000 description 1
- 101000890951 Homo sapiens Type-2 angiotensin II receptor Proteins 0.000 description 1
- 108010018951 Interleukin-8B Receptors Proteins 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108010008409 Muscarinic M5 Receptor Proteins 0.000 description 1
- 102100035624 Muscarinic acetylcholine receptor M1 Human genes 0.000 description 1
- 108050007299 Muscarinic acetylcholine receptor M1 Proteins 0.000 description 1
- 102100036425 Muscarinic acetylcholine receptor M2 Human genes 0.000 description 1
- 108050006825 Muscarinic acetylcholine receptor M2 Proteins 0.000 description 1
- 102100036423 Muscarinic acetylcholine receptor M3 Human genes 0.000 description 1
- 108050008508 Muscarinic acetylcholine receptor M3 Proteins 0.000 description 1
- 102100025896 Muscarinic acetylcholine receptor M4 Human genes 0.000 description 1
- 108050008897 Muscarinic acetylcholine receptor M4 Proteins 0.000 description 1
- 241000244206 Nematoda Species 0.000 description 1
- 102100035314 Neuromedin-U receptor 1 Human genes 0.000 description 1
- 101710098695 Neuromedin-U receptor 1 Proteins 0.000 description 1
- 102000017922 Neurotensin receptor Human genes 0.000 description 1
- 108060003370 Neurotensin receptor Proteins 0.000 description 1
- 102100026700 Olfactory receptor 2C1 Human genes 0.000 description 1
- 101710139936 Olfactory receptor 2C1 Proteins 0.000 description 1
- 102100037776 Olfactory receptor 6A2 Human genes 0.000 description 1
- 108050002069 Olfactory receptors Proteins 0.000 description 1
- 102000016978 Orphan receptors Human genes 0.000 description 1
- 108070000031 Orphan receptors Proteins 0.000 description 1
- 102100028139 Oxytocin receptor Human genes 0.000 description 1
- 108090000876 Oxytocin receptors Proteins 0.000 description 1
- 101710125072 Phosrestin-2 Proteins 0.000 description 1
- 101100244562 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) oprD gene Proteins 0.000 description 1
- 102100022135 S-arrestin Human genes 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 102100025750 Sphingosine 1-phosphate receptor 1 Human genes 0.000 description 1
- 102000004852 Thyrotropin-releasing hormone receptors Human genes 0.000 description 1
- 108090001094 Thyrotropin-releasing hormone receptors Proteins 0.000 description 1
- 102100040372 Type-2 angiotensin II receptor Human genes 0.000 description 1
- 102000004136 Vasopressin Receptors Human genes 0.000 description 1
- 108090000643 Vasopressin Receptors Proteins 0.000 description 1
- 239000007801 affinity label Substances 0.000 description 1
- 108020004101 alpha-2 Adrenergic Receptor Proteins 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 108010014494 beta-1 Adrenergic Receptors Proteins 0.000 description 1
- 108010014499 beta-2 Adrenergic Receptors Proteins 0.000 description 1
- 108010032969 beta-Arrestin 1 Proteins 0.000 description 1
- 108010032967 beta-Arrestin 2 Proteins 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229930193282 clathrin Natural products 0.000 description 1
- 230000008045 co-localization Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000000942 confocal micrograph Methods 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 108700023159 delta Opioid Receptors Proteins 0.000 description 1
- 102000048124 delta Opioid Receptors Human genes 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000030609 dephosphorylation Effects 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 108091005708 gustatory receptors Proteins 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229920000592 inorganic polymer Polymers 0.000 description 1
- 102000010681 interleukin-8 receptors Human genes 0.000 description 1
- 108010038415 interleukin-8 receptors Proteins 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229920000620 organic polymer Polymers 0.000 description 1
- JMANVNJQNLATNU-UHFFFAOYSA-N oxalonitrile Chemical compound N#CC#N JMANVNJQNLATNU-UHFFFAOYSA-N 0.000 description 1
- 102000014187 peptide receptors Human genes 0.000 description 1
- 108010011903 peptide receptors Proteins 0.000 description 1
- 230000016732 phototransduction Effects 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000005258 radioactive decay Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 230000008786 sensory perception of smell Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000006442 vascular tone Effects 0.000 description 1
- 230000003600 vasopressic effect Effects 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1089—Design, preparation, screening or analysis of libraries using computer algorithms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5076—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving cell organelles, e.g. Golgi complex, endoplasmic reticulum
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2503/00—Use of cells in diagnostics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
- G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Food Science & Technology (AREA)
- Wood Science & Technology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Bioinformatics & Computational Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27533901P | 2001-03-13 | 2001-03-13 | |
| US60/275,339 | 2001-03-13 | ||
| US10/095,620 US20030013137A1 (en) | 2001-03-13 | 2002-03-12 | Automated methods of detecting receptor activity |
| US10/095,620 | 2002-03-12 | ||
| PCT/US2002/007434 WO2002073199A1 (en) | 2001-03-13 | 2002-03-13 | Automated methods of detecting receptor activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2440683A1 true CA2440683A1 (en) | 2002-09-19 |
Family
ID=26790404
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002440683A Abandoned CA2440683A1 (en) | 2001-03-13 | 2002-03-13 | Automated methods of detecting receptor activity |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US20030013137A1 (enExample) |
| EP (1) | EP1386154A4 (enExample) |
| JP (1) | JP2004532978A (enExample) |
| AU (1) | AU2002248597B2 (enExample) |
| CA (1) | CA2440683A1 (enExample) |
| WO (1) | WO2002073199A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4969002B2 (ja) | 1999-06-08 | 2012-07-04 | ユニバーシテイ・オブ・アイオワ・リサーチ・フアウンデーシヨン | ｒＡＡＶ形質導入を増加するための化合物および方法 |
| US7163800B2 (en) * | 2000-11-03 | 2007-01-16 | Molecular Devices Corporation | Methods of screening compositions for G protein-coupled receptor desensitization inhibitory activity |
| US20050136431A1 (en) * | 2000-11-03 | 2005-06-23 | Oakley Robert H. | Methods of screening compositions for G protein-coupled receptor desensitization inhibitory activity |
| WO2003016486A2 (en) * | 2001-08-16 | 2003-02-27 | Sloan Kettering Institute For Cancer Research | Bio-synthetic photostimulators and methods of use |
| AU2003228956B2 (en) * | 2002-05-13 | 2009-10-01 | Mds Analytical Technologies (Us) Inc. | Constitutively translocating cell line |
| FR2851379B1 (fr) * | 2003-02-18 | 2008-02-01 | Cit Alcatel | Convertisseur en transfert direct d'energie |
| WO2004038005A2 (en) * | 2002-10-25 | 2004-05-06 | Norak Biosciences, Inc. | Methods of identifying reduced internalization transmembrane receptor agonists |
| AU2004227358B8 (en) * | 2003-03-31 | 2009-12-10 | Targeted Genetics Corporation | Compounds and methods to enhance rAAV transduction |
| AU2004257228B8 (en) * | 2003-07-09 | 2009-01-08 | Life Technologies Corporation | Method for assaying protein-protein interaction |
| ATE457499T1 (de) * | 2004-12-09 | 2010-02-15 | Cellomics Inc | Automatisiertes verfahren und system zur einstellung von bildanalyseparametern zur steuerung von bildanalyseoperationen |
| JP2007006830A (ja) * | 2005-07-01 | 2007-01-18 | Olympus Corp | 細胞内の顆粒状構造物の測定方法 |
| CA2651180A1 (en) * | 2006-04-28 | 2007-11-08 | University Of Iowa Research Foundation | Methods and compounds to alter virus infection |
| CN101063657A (zh) * | 2006-04-29 | 2007-10-31 | 中国科学院上海生命科学研究院 | 在活体细胞中筛选配体与受体结合的方法和系统 |
| EP2422194B1 (en) | 2009-04-20 | 2014-12-17 | Agency For Science, Technology And Research | Vesicular system and uses thereof |
| WO2013078362A1 (en) * | 2011-11-23 | 2013-05-30 | Promega Corporation | Compositions and methods for monitoring transmembrane trafficking |
| WO2014176524A2 (en) * | 2013-04-25 | 2014-10-30 | The Trustees Of The University Of Pennsylvania | Opioid detection based on high quality graphene transistor arrays and a synthetic mu receptor |
| US11702672B2 (en) | 2016-02-08 | 2023-07-18 | University Of Iowa Research Foundation | Methods to produce chimeric adeno-associated virus/bocavirus parvovirus |
| EP3426787A1 (en) | 2016-03-07 | 2019-01-16 | University of Iowa Research Foundation | Aav-mediated expression using a synthetic promoter and enhancer |
| US12173305B2 (en) | 2016-05-26 | 2024-12-24 | University Of Iowa Research Foundation | cis and trans requirements for terminal resolution of human bocavirus 1 |
| US11142775B2 (en) | 2017-01-13 | 2021-10-12 | University Of Iowa Research Foundation | Bocaparvovirus small noncoding RNA and uses thereof |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4219335A (en) * | 1978-09-18 | 1980-08-26 | E. I. Du Pont De Nemours And Company | Immunochemical testing using tagged reagents |
| US4324633A (en) * | 1980-10-20 | 1982-04-13 | Lovejoy Curtis N | Electrolytic apparatus for treating continuous strip material |
| US5972629A (en) * | 1984-08-17 | 1999-10-26 | The Scripps Research Institute | Method for characterizing antigenic reactivity of biological sample |
| US4908773A (en) * | 1987-04-06 | 1990-03-13 | Genex Corporation | Computer designed stabilized proteins and method for producing same |
| US5744101A (en) * | 1989-06-07 | 1998-04-28 | Affymax Technologies N.V. | Photolabile nucleoside protecting groups |
| US5548661A (en) * | 1991-07-12 | 1996-08-20 | Price; Jeffrey H. | Operator independent image cytometer |
| US5324633A (en) * | 1991-11-22 | 1994-06-28 | Affymax Technologies N.V. | Method and apparatus for measuring binding affinity |
| DE4138621A1 (de) * | 1991-11-25 | 1993-06-17 | Boehringer Ingelheim Int | Verfahren zum screenen von substanzen mit modulierender wirkung auf einen rezeptorabhaengigen zellulaeren signaluebertragungsweg |
| US5670113A (en) * | 1991-12-20 | 1997-09-23 | Sibia Neurosciences, Inc. | Automated analysis equipment and assay method for detecting cell surface protein and/or cytoplasmic receptor function using same |
| US5912122A (en) * | 1993-06-04 | 1999-06-15 | Sibia Neurosciences, Inc. | Nucleic acids encoding and method for detecting nucleic acid encoding human metabotropic glutamate receptor subtype mGluR6 |
| AU1297995A (en) * | 1993-11-26 | 1995-06-13 | Lawrence B Hendry | Design of drugs involving receptor-ligand-dna interactions |
| GB9403600D0 (en) * | 1994-02-24 | 1994-04-13 | Univ Glasgow | Three dimensional hormone structure |
| US5521705A (en) * | 1994-05-12 | 1996-05-28 | Oldenbourg; Rudolf | Polarized light microscopy |
| US5463564A (en) * | 1994-09-16 | 1995-10-31 | 3-Dimensional Pharmaceuticals, Inc. | System and method of automatically generating chemical compounds with desired properties |
| EP0829810A4 (en) * | 1995-03-17 | 1999-07-14 | Kureha Chemical Ind Co Ltd | PROCESSOR FOR BIOCHEMICAL INFORMATION, METHOD FOR PROCESSING BIOCHEMICAL INFORMATION AND RECORDING MEDIUM FOR BIOCHEMICAL INFORMATION |
| US6219622B1 (en) * | 1995-03-24 | 2001-04-17 | University Of Guelph | Computational method for designing chemical structures having common functional characteristics |
| US6100026A (en) * | 1995-04-25 | 2000-08-08 | Irori | Matrices with memories and uses thereof |
| US6025129A (en) * | 1995-04-25 | 2000-02-15 | Irori | Remotely programmable matrices with memories and uses thereof |
| US6017496A (en) * | 1995-06-07 | 2000-01-25 | Irori | Matrices with memories and uses thereof |
| US5545531A (en) * | 1995-06-07 | 1996-08-13 | Affymax Technologies N.V. | Methods for making a device for concurrently processing multiple biological chip assays |
| US5770176A (en) * | 1995-12-08 | 1998-06-23 | Chiron Diagnostics Corporation | Assays for functional nuclear receptors |
| US6027890A (en) * | 1996-01-23 | 2000-02-22 | Rapigene, Inc. | Methods and compositions for enhancing sensitivity in the analysis of biological-based assays |
| JP3733392B2 (ja) * | 1996-03-05 | 2006-01-11 | イーストマン コダック カンパニー | 画像の構図変化検出方法 |
| US5989835A (en) * | 1997-02-27 | 1999-11-23 | Cellomics, Inc. | System for cell-based screening |
| US5804436A (en) * | 1996-08-02 | 1998-09-08 | Axiom Biotechnologies, Inc. | Apparatus and method for real-time measurement of cellular response |
| US5891646A (en) * | 1997-06-05 | 1999-04-06 | Duke University | Methods of assaying receptor activity and constructs useful in such methods |
| US5972639A (en) * | 1997-07-24 | 1999-10-26 | Irori | Fluorescence-based assays for measuring cell proliferation |
| US6221612B1 (en) * | 1997-08-01 | 2001-04-24 | Aurora Biosciences Corporation | Photon reducing agents for use in fluorescence assays |
| US5987390A (en) * | 1997-10-28 | 1999-11-16 | Smithkline Beecham Corporation | Methods and systems for identification of protein classes |
| ATE231617T1 (de) * | 1998-07-13 | 2003-02-15 | Cellomics Inc | Auf zellen basiertes screening-system |
| US6203987B1 (en) * | 1998-10-27 | 2001-03-20 | Rosetta Inpharmatics, Inc. | Methods for using co-regulated genesets to enhance detection and classification of gene expression patterns |
| US6221600B1 (en) * | 1999-10-08 | 2001-04-24 | Board Of Regents, The University Of Texas System | Combinatorial oligonucleotide PCR: a method for rapid, global expression analysis |
-
2002
- 2002-03-12 US US10/095,620 patent/US20030013137A1/en not_active Abandoned
- 2002-03-13 JP JP2002572410A patent/JP2004532978A/ja active Pending
- 2002-03-13 EP EP02717608A patent/EP1386154A4/en not_active Withdrawn
- 2002-03-13 AU AU2002248597A patent/AU2002248597B2/en not_active Expired
- 2002-03-13 WO PCT/US2002/007434 patent/WO2002073199A1/en not_active Ceased
- 2002-03-13 CA CA002440683A patent/CA2440683A1/en not_active Abandoned
-
2003
- 2003-07-29 US US10/629,176 patent/US20040029190A1/en not_active Abandoned
-
2005
- 2005-03-21 US US11/084,928 patent/US7455982B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US7455982B2 (en) | 2008-11-25 |
| US20040029190A1 (en) | 2004-02-12 |
| US20050181423A1 (en) | 2005-08-18 |
| US20030013137A1 (en) | 2003-01-16 |
| WO2002073199A1 (en) | 2002-09-19 |
| AU2002248597B2 (en) | 2008-01-31 |
| EP1386154A4 (en) | 2004-09-15 |
| JP2004532978A (ja) | 2004-10-28 |
| EP1386154A1 (en) | 2004-02-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2440683A1 (en) | Automated methods of detecting receptor activity | |
| Daly et al. | Fluorescent ligands, antibodies, and proteins for the study of receptors | |
| JP3683591B2 (ja) | 細胞に基づくスクリーニングシステム | |
| Kallal et al. | Using green fluorescent proteins to study G-protein-coupled receptor localization and trafficking | |
| Eidne et al. | Applications of novel resonance energy transfer techniques to study dynamic hormone receptor interactions in living cells | |
| DE69829973T2 (de) | Methode mit hohem durchsatz | |
| EP2073013B1 (en) | Method of identifying transmembrane protein-interacting compounds | |
| JP3466568B2 (ja) | 細胞ベースのスクリーニング用のシステム | |
| Milligan | High-content assays for ligand regulation of G-protein-coupled receptors | |
| AU2002248597A1 (en) | Automated methods of detecting receptor activity | |
| US7163800B2 (en) | Methods of screening compositions for G protein-coupled receptor desensitization inhibitory activity | |
| Milligan et al. | G protein-coupled receptor fusion proteins in drug discovery | |
| Eglen et al. | Photoproteins: important new tools in drug discovery | |
| Adie et al. | CypHer 5: a generic approach for measuring the activation and trafficking of G protein-coupled receptors in live cells | |
| Mellentin-Michelotti et al. | Determination of ligand binding affinities for endogenous seven-transmembrane receptors using fluorometric microvolume assay technology | |
| CN101432624B (zh) | 在活体细胞中筛选配体与受体结合的方法和系统 | |
| US7297503B2 (en) | Methods of identifying reduced internalization transmembrane receptor agonists | |
| Eglen | An overview of high throughput screening at G protein coupled receptors | |
| Okamoto et al. | Human chorionic gonadotropin (hCG) beta-core fragment is produced by degradation of hCG or free hCG beta in gestational trophoblastic tumors: a possible marker for early detection of persistent postmolar gestational trophoblastic disease | |
| Oakley et al. | TRANSFLUOR Provides a Universal Cell-Based Assay for Screening G-Protein-Coupled Receptors | |
| Fu et al. | The identification of high-affinity G protein-coupled receptor ligands from large combinatorial libraries using multicolor quantum dot-labeled cell-based screening | |
| US20070196865A1 (en) | Methods Of Screening Compositions For G Protein-Coupled Receptors Aganist Agonists | |
| Heilker | High content screening to monitor G protein-coupled receptor internalisation | |
| US20050136431A1 (en) | Methods of screening compositions for G protein-coupled receptor desensitization inhibitory activity | |
| Zheng et al. | Real-time endocytosis imaging as a rapid assay of ligand-GPCR binding in single cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |